Cologuard – Less Effective and More Expensive?
A recent study looked at the effectiveness and cost of different colon cancer screening options and the results were clear: Cologuard was less effective and more expensive than other screening options.
The researchers ultimately concluded, “Compared to no screening, triennial mtSDNA screening reduces CRC incidence and mortality at acceptable costs. However, compared to nearly all other CRC screening strategies reimbursed by CMS it is less effective and considerably more costly, making it an inefficient screening option.”
Read more about Cologuard
Read the study: Plos One
Source: Beckers ASC